Company news
Oncolys BioPharma, Inc. news in 2023
Oncolys BioPharma, Inc.'s news releases, calls and decks from 2023, newest first.
Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma
December 19, 2023
Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy
October 16, 2023
Non-consolidated Financial Results for the Three Months Ended March 31, 2023
May 12, 2023